ABOUT US
关于我们

久诚无限、瑞纳百川

创立于2002年的久瑞集团,长期专注于生物科技与医药健康产品的研发和推广,以创新技术为核心,产学研一体打造专业品牌,在生物医药、免疫细胞、基因工程、医学检测、医学美容等领域,均取得了骄人成就,2020年被列入国家高新技术企业行列。














久瑞在全国范围内建立完善的市场营销体系、管理体系、学术体系,拥有分布于全国各地的优质医疗与医学专业机构3000多家,业务网络覆盖三十多个省市与自治区。在医药领域,久瑞以核心企业——浙江艾美瑞医药有限公司作为研发与销售的战略平台,持续输出优质产品与服务,特别在儿科、中枢神经等药物领域,多年来保持着行业领先的市场地位。

在科研与学术方面,久瑞坚持国际化视野,2003年在欧洲建立全球医学研究中心,并与国内知名重点高校(复旦大学、上海交通大学、华东理工大学、中国药科大学、中南大学等)开展产学研合作;与中华医学会、中国医师协会、中国药物滥用防治协会等国家一级单位保持学术合作,切实推进与执行药物规范使用制度;相继建立与完善覆盖全国范围的医疗专家资源库。

在智慧医疗领域,久瑞在宁波艾瑞斯科技有限公司基础上搭建智慧医疗产业平台,推出全院级医疗物资智能化解决方案、AI智能药房运营方案、智慧病区管理方案,为各级医疗服务机构提供安全、高效的医疗服务智能化集成系统。

在医学检测领域,久瑞同样坚持产学研一体的发展战略,其中作为全国首创的“基于流式细胞技术平台研发的亚细胞结构损伤检测项目”,目前处于国内行业领先水平。

2022年,久瑞集团在宁波高新区布局艾瑞斯智慧医疗产业园,首期投资超6亿元,园区由中国美院风景建筑设计院知名大师倾力设计,营运面积5万平米,拟建设久瑞国际生物医药研究中心、智慧医疗装备生产中心、细胞医学试剂生产及检测中心、久瑞商学院、久瑞院士工作站、久瑞医疗产业联盟等相关主体。

强大的团队执行力和企业凝聚力是久瑞持续发展的保证,我们坚持“亲和、责任、效率”的企业精神,持续打造企业核心竞争力,创建幸福企业,致力于合作伙伴、员工与企业三者价值的共同成就。不忘初心,以民众健康为己任,以赋有品质的产品和服务,让人们生活更美好。

JOYLUCKY Group was established in 2002, has been focusing on the research and promotion of biotechnology and pharmaceutical health products for a long time. Innovative technology as the core, with the combination of industry, universities and research institute to create a professional brand. In the fields of biomedicine, immune cells, genetic engineering, medical testing, medical cosmetology etc. JOYLUCKY has achieved remarkable achievements and was listed as a national high-tech enterprise in 2020.

JOYLUCKY has established a comprehensive marketing system nationwide, with over 3000 high-quality medical and medical professional institutions distributed throughout the country, and its business network covering more than 30 provinces, cities, and autonomous regions. In the pharmaceutical field, JOYLUCKY uses its core enterprise - Zhejiang A-timely medical Co., Ltd. - as a strategic platform for research and sales, continuously exporting high-quality products and services, especially in the fields of pediatrics, central nervous system, and other drugs. For many years, JOYLUCKY has maintained a leading market position in the industry.

In terms of scientific research and academia, JOYLUCKY adheres to an international perspective and established a global medical research center in Europe in 2003. It also collaborates with well-known domestic universities (Fudan University, Shanghai JiaoTong University, East China University of Science and Technology, China Pharmaceutical University, Central South University, etc.) to carry out industry-university-research cooperation; Maintain academic cooperation with national first level units such as the Chinese Medical Association, the Chinese Medical Association, and the China Association for the Prevention and Control of Drug Abuse, and effectively promote and implement the system of standardized drug use; We have successively established and improved a medical expert resource center covering the whole country.

In the field of smart medical care, JOYLUCKY has built a smart medical care industry platform based on Ningbo Iris Technology Co., Ltd., launched hospital level intelligent medical material programs, AI intelligent pharmacy operation programs, and smart ward management programs, providing safe and efficient intelligent medical service integration systems for medical service institutions at all levels.

In the field of medical testing, JOYLUCKY also adheres to the development strategy of integrating industry, academia, and research. As the first “subcellular structural damage detection project developed based on flow cytometry technology” project in China, it is currently at the leading level in the domestic industry.

In 2022, JOYLUCKY Group will layout the Iris Smart Medical Industry Park in Ningbo High tech Zone, with an initial investment of over 600 million Chinese yuan. The park will be designed by famous masters from the Landscape Architecture Design Institute of the Chinese Academy of Fine Arts, with an operating area of 50000 square meters. It plans to build JOYLUCKY International Biomedical Research Center, Smart Medical Equipment Production Center, Cell Medicine Reagent Production and Testing Center, JOYLUCKY Business School, and JOYLUCKY Academician Workstation,such that entities with the JOYLUCKY Medical Industry Alliance.

Strong team execution and corporate cohesion are the guarantees for the sustainable development of JOYLUCKY. We adhere to the corporate spirit of "affinity, responsibility, and efficiency", continuously build the core competitiveness of the enterprise, create a happiness enterprise, and strive to achieve the common values of partners, employees, and the company. Lastly, we will never forget our original intention --- take public health as our responsibility, and provide high-quality products and services to make people's lives better.

COMPANY DEVELOPMENT HISTORY
公司发展历程
2002.6
2005
2016
2019
2021
2023
2013
2008
2003
2006
2017
2020
2022
2015
2012
创立久瑞生物科技药业有限公司
初涉医药领域,与国内数十家大型综合医院开启合作。
成立儿科事业部四大儿科黄金单品相继上市;
中国医师协会中华医学会等一级学术组织开启学术战略合作;
持续耕耘,确立在全国医药销售行业的优势地位。
中国药物滥用防治协会合作,
参与《苯二氮䓬类药物临床使用专家共识》的修订与出版。
在精神科领域,首个代表医药企业参与修订的
《中国失眠障碍综合防治指南》出版;
开始布局IVD领域,以“诊疗一体化”巩固营销终端竞争力。
成立宁波译美瑞医疗科技有限公司,开启医疗机械的研发与生产;
升级成立浙江艾美瑞医药有限公司
树立集团化战略优势,新三十年规划发布实施。
集团总部大楼“艾瑞斯智慧科技医疗产业园”启动建设;
多个化药产品与中成药项目投入研发,布局未来大单品与大健康市场。
业务精英训练营”开营,高度赋能全国业务战线的持续经营能力,指导业务升级,实现全面多赢和可持续发展。
成立精神科事业部,致力于精神科药物领域的发展与学术推广;
加快“学术型企业组织”建设,设立企业医学专家库、博士后站。
打造专业化销售推广体系,确立与完善“产品销售、
学术为先”的市场理念;
建立起覆盖全国的一二三级市场医药销售网络;
在欧洲成立法迪曼医学研究中心,开启全球化医药研究与技术合作。
首个核苷类抗病毒药物全国上市
快速打开市场并成为该类型药物主导品牌。
成立皮肤科事业部,建立医学护肤品生产基地;
在欧洲创立”DSA数字肌肤研究会”,首创PCN金字塔数字护肤系统
多项核心技术获专利保护。
获得国家高新技术企业认证;
细胞医学检测等项目推向全国市场;
建立医药集中研发平台,新药研发进入快车道。
参与国内首部《镇静催眠药临床使用指南》的修订与出版;
两个中枢神经领域核心大产品项目投入研发。
成立宁波久瑞生物工程有限公司
成立医药研发中心、细胞检测中心,基因工程实验室,
建立现代化工厂。
阳光同盟计划”开班,深度帮扶全国战略合作伙伴专业化升级。
INDUSTRIAL DISTRIBUTION MAP
产业分布版图
国际原料
医疗产业
智慧医疗
医美管理
研究机构
检测机构
生产企业
生物医药
药械研发
美妆护肤
韩国B.O.P生物公司
艾瑞斯智慧医疗科技产业园
宁波译美瑞医疗科技有限公司
法迪曼国际医学研发中心欧洲DSA数字肌肤研究会
宁波泛肽生物科技有限公司
宁波久瑞生物工程有限公司
浙江艾美瑞医药有限公司
宁波久瑞艾美科技有限公司
宁波法迪曼生物科技有限公司
宁波艾瑞斯科技有限公司